Clay Siegall’s most recent posts are composed of biotech inventions that are expected to make a big transformation with patients who have various diseases. The following are some of the said biotech innovations:
Cancer therapies like Genentech/Roche trastuzumab (Herceptin and Celgene’s Lenalidomide (Revlimid).
- HIV therapies like Gilead Sciences’ mixture of tenofovir (Atripla), emtricitabine, and efavirenz.
- Enhanced flu vaccines
- Treatments for hepatitis C like telaprevir from Vertex Pharmaceuticals.
- Tumor vaccines like Dendreon’s sipuleucel-T (Provenge)
As someone who is specializing in antibody technologies, Siegall’s blogs pertain to the ongoing researches that are being done in order to have a better treatment for numerous diseases that individuals usually have. His posts show his dedication to his craft and the need to get effective results in the long run.
Clay Siegall is the co-founder of Seattle Genetics, which was established in 1998. He is the CEO, President and Board of Directors member of the company. Seattle Genetics has a compilation of varied pre-clinical and clinical products that are being manufactured for different autoimmune and cancer indications. It is likewise a leading figure in technologies that explore antibodies, particularly the antibody drug conjugate (ADC).
Dr. Siegall handles Seattle Genetics’ fund raising activities that secured over $330 million from private and public donations. Moreover, Seattle Genetics joined numerous strategic collaborations, which included a restricted worldwide deal for SGN-40 with Genentech, which was estimated to be above $860 million. The company also entered into several ADC partnerships that include Progenics, CuraGen, Bayer, Genentech, and Medlmmune that has produced $65 million and more ever since 2001.
The main core of Dr. Clay Siegall’s achievements are his dedication and focus on vital research along with being conscientious of its development and implementation. His desire to help patients and ease their pain has been his guide and motivation to continuously do research and find a cure that would be beneficial for everyone. These driving factors have assisted Dr. Siegall in taking the company into new heights with regards to advance research.
Clay Siegall is still as committed as ever in leading new scientific researches, and he is continually looking for means and ways to take medical research to new heights. His community work includes publishing blogs for new research discoveries, and as of this time he has already published over 70 scientific articles.
Dr. Siegall earned his Ph. D. in Genetics and B.S. in Zoology from the George Washington University and the University of Maryland respectively.